Skip to main
ENOV
ENOV logo

Enovis Corp (ENOV) Stock Forecast & Price Target

Enovis Corp (ENOV) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 54%
Buy 38%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

Enovis Corp has demonstrated positive financial momentum, with its adjusted gross margin increasing by 150 basis points year-over-year, reaching 60.1%, which surpassed consensus estimates. The company also reported significant growth in its Reconstructive segment, with proforma sales rising by 10.0% to $274.0 million in the fourth quarter of 2024, reflecting an improvement over the prior quarter's growth. Furthermore, the expectation of continued increases in gross and operating margins, alongside anticipated accretive acquisitions, supports a favorable outlook for Enovis's EBITDA and EPS growth outpacing revenue growth.

Bears say

Enovis Corp is facing a negative outlook primarily due to decreasing revenue estimates, with projections for 2024 and 2025 adjusted down to $2.100 billion and $2.244 billion, respectively. Additionally, the company's Prevention & Recovery segment has experienced growth deceleration, and there are identified risks including potential market share loss to competitors and slow growth in the orthopedic market. Furthermore, ongoing dissynergies related to Lima have created notable headwinds, impacting overall financial performance and stability.

Enovis Corp (ENOV) has been analyzed by 13 analysts, with a consensus rating of Buy. 54% of analysts recommend a Strong Buy, 38% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Enovis Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Enovis Corp (ENOV) Forecast

Analysts have given Enovis Corp (ENOV) a Buy based on their latest research and market trends.

According to 13 analysts, Enovis Corp (ENOV) has a Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $64.15, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $64.15, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Enovis Corp (ENOV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.